LianBio

LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. It develops a portfolio of clinically validated product candidates for cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. The company was founded by Konstantin Poukalov on July 17, 2019 and is headquartered in Princeton, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) --  LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that management will participate in the Bank of America Securities 2022 Healthcare Conference being held in person in Las Vegas on May 10-13, 2022. Management is scheduled to participate in a fireside chat on May 12, 2022 at 9:20 a.m.

LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference

LianBio Holds Development and Commercialization Rights to TP-03 in Greater China LianBio Holds Development and Commercialization Rights to TP-03 in Greater China

LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

LianBio to Continue Development of Camzyos in China and Other Asian Territories LianBio to Continue Development of Camzyos in China and Other Asian Territories

U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to Greater China and Asia Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to Greater China and Asia

LianBio Announces Formation of Scientific Advisory Board

Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics to Greater China Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics to Greater China

LianBio's Partner ReViral Enters into Acquisition Agreement with Pfizer

SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors.

LianBio Appoints Wei Wei Chen to Board of Directors

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing

LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Company's principal auditor is located in the United States and is currently inspected by the PCAOB Company's principal auditor is located in the United States and is currently inspected by the PCAOB

LianBio Issues Statement Regarding the HFCAA

The company is focused on bringing innovative therapies to China and major Asian markets through partnerships with other biotech/pharma companies.

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation in China for mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM).

LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China

The stock price of LianBio (NASDAQ: LIAN) increased by 19.67% today. This is why it happened.

LianBio Stock (LIAN): Why The Price Surged Today

EXPLORER-CN trial designed to support regulatory filing in Mainland China EXPLORER-CN trial designed to support regulatory filing in Mainland China

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that infigratinib has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the special Named Patient Program (NPP), for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. The first cholangiocarcinoma patient in China was prescribed and treated with infigratinib at Bo'ao Super Hospital in Mainland China, marking the first prescription of infigratinib outside of North America.

LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Atour Lifestyle Holdings Ltd

Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.

Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume

Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.

China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans

LianBio LIAN, -11.38% got off to a rocky start as a public company, as the first trade of the shares of biotechnology company with operations in the U.S. and China was 3.1% below the initial public offering price, reversing early indications of an upbeat open. The company said Sunday evening that its IPO priced at $16 a share, or in the middle of the expected range, as the company sold 20.31 shares to raise $325.0 million.

LianBio stock opens below the IPO price, reversing early indications of a rally

LianBio LIAN, -2.22% is set to go public Monday, after the biotechnology company with operations in the U.S. and China said its initial public offering priced at $16 a share, in the middle of the expected range of between $15 and $17 a share. The company offered 20.31 million American depositary shares in the IPO to raise $325.0 million.

LianBio to go public as IPO prices in middle of expected range, as the biotech was valued at about $1.7 billion

SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the pricing of its initial public offering of 20,312,500 American depositary shares (“ADSs”) at a public offering price of $16.00 per ADS, for gross proceeds of approximately $325.0 million, before deducting underwriting discounts and commissions and offering expenses. Each ADS represents one ordinary share of LianBio, and all of the ADSs are being offered by LianBio. In addition, LianBio has granted the underwriters a 30-day option to purchase up to 3,046,875 additional ADSs at the initial public offering price, less underwriting discounts and commissions.

News for LianBio Stock (LIAN)